Q & A Highlights

Q: Regarding the upcoming brepocitinib launch in dermatomyositis (DM), what metrics will the company provide to track the initial launch, and what are the implications of baseline characteristics in the PH-ILD (PHocus) study on the bar for success? A: CEO Matt Gline stated that beyond a "slow and steady" launch, top-line metrics will be visible in quarterly financials, but the company will not provide a ton of early detail. For PH-ILD, he noted the study was designed with care around emphysema allowances to maximize benefit. He expects a clearer signal on PVR, but does not expect much clarity on six-minute walk distance, which is not essential for the go/no-go decision.

Q: For the Mosley (PH-ILD) program, what type of six-minute walk distance would be relevant to clinicians and patients if a large trial were run? A: Gline explained that PH-ILD patients are very sick with few options, and the focus should be on having an approvable therapy rather than a specific numerical bar. He emphasized that six-minute walk is a noisy clinical artifice, and if the drug effectively vasodilates and improves PVR, patients will see significant benefit in daily life.

Q: Could you discuss the cadence of formulary reviews for rare disease drugs, given that P&T committees often wait six months for mass-market drugs? A: Gline said the company is having normal engagement with the payer community and is focused on ensuring physician and patient access. He noted that while formulary processes are similar across diseases, the company has a dedicated team at Priovant to handle medical exception procedures so patients and physicians don't have to worry about coverage delays.

Q: Beyond the listed programs, what pipeline and product opportunities could see new study initiations over the next year? A: Gline stated that every program in the pipeline, including potentially undisclosed ones, could announce new trials or indications in the next year. He confirmed the company has specific ideas and is actively preparing to initiate programs, with real progress being made across all molecules.

Q: How translatable are PVR reductions from PAH patients to the PH-ILD population in the PHocus study, and could disease aspects influence the magnitude of PVR reduction? A: Gline acknowledged that translation from PAH to PH-ILD is the fundamental question being answered. While Phase 1 data in PAH patients looks good on PVR, the lungs of PH-ILD patients differ, potentially affecting pharmacodynamics. However, he believes inhaled vasodilators should deliver drug to healthy lung tissue and be effective, though the study will ultimately provide the answer.

Q: Given JAK class safety concerns, how are physicians receiving brepocitinib for DM, especially since DM patients have higher underlying cancer risk? A: Gline noted that dermatomyositis is a "poster child" for JAK use because patients have no other options. He emphasized that current therapies like high-dose steroids carry worse safety risks than JAK inhibitors. Physicians are comfortable using these agents, and while the label will include black box warnings, doctors expect this and are not overly concerned given the severity of the disease.

Q: What percentage of DM patients are on off-label JAKs, and would they rapidly switch to brepocitinib? Also, what is the biggest risk for the Phase 3 NIU trial? A: Gline said low-to-mid single-digit percentages of DM patients have JAK experience, and some physicians using off-label JAKs expect to switch patients. For NIU, the biggest risk is variability in placebo response rates, which is common in immunology trials. He acknowledged geographic variation as a feature of such studies but remains optimistic given the compelling Phase 2 data.

Q: What launch analogs are you assessing for brepocitinib in DM, either patient or market share curves? A: Gline stated there has never been a targeted therapy launch in dermatomyositis, so there is no good analog. He emphasized the company is focused on the DM opportunity itselfthe doctors, patients, and benefitsrather than comparing to other launches, as being a pioneering indication requires charting its own course.

Q: For the difficult-to-treat RA program (1402), what is the strategy? Would one or two more studies be needed, and what should be expected from the randomized withdrawal phase? A: Gline said the company will provide a full update later this year, including randomized withdrawal data and an FDA conversation planned for the fall. The results will inform whether the study can serve as one of two pivotal studies. He noted the high response rates in the open-label period set a higher bar for hitting a P-value in the randomized withdrawal section.

Q: For the Graves' disease program, how is the company thinking about the competitive landscape, and what is the approach to future studies for 1402? A: Gline dismissed competition concerns, noting Graves' disease has had no novel therapy since the 1950s-60s, leaving massive unmet need. He stated 1402 will be first to market, allowing the company to influence treatment paradigms. He emphasized building the market rather than beating competitors, and the company will leverage learnings from studies and physician engagement for future development.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .